Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Syntaxin wins collaborative DTI Grant to investigate biopharmaceutical processing

Salisbury, UK, 6 July 2006 - Syntaxin Ltd (Syntaxin), a newly formed biopharmaceutical company focusing on the discovery and development of new medicines derived from bacterial toxins to treat chronic diseases, has been awarded a collaborative R&D grant of over £1.2 million from the UK Department for Trade and Industry. Syntaxin will be collaborating with The Advanced Centre for Biochemical Engineering (ACBE) at UCL (University College London), and the UK Health Protection Agency (HPA) to develop enhanced methods for the bioprocessing of complex proteins that can be used as biopharmaceuticals to treat neurological, respiratory and metabolic diseases.

Syntaxin will design the therapeutics to be investigated using its expertise and intellectual property in designing novel recombinant proteins and candidate biopharmaceutical agents. The ACBE is the UK focus for bioprocess research, and will apply its expertise in ultra scale-down experimentation and process modelling to rapidly explore novel bioprocess routes and their optimisation. The HPA will then undertake the scale-up of these methodologies in order to develop manufacturing processes for Syntaxin’s biotherapeutic candidates.

Dr Keith Foster, Chief Scientific Officer of Syntaxin, in announcing this award, said: “Syntaxin has a product development platform that can generate a range of biotherapeutic molecules with several common features: these include a common expression vehicle, and shared protein domains. This award provides us with an excellent opportunity to work with two world-class institutions to develop new and improved manufacturing processes that we will be able to apply to our development programmes. The knowledge that we will generate through this programme will accelerate our ability to bring important new medicines for chronic diseases to the market.”

Dr Roger Gilmour, Director of the HPA’s centre at Porton Down said: “Process development and scale-up for the manufacture of biologics to good manufacturing practice standards is one of the key capabilities of the Agency, and we are delighted to be able to help Syntaxin develop new medicines.”

For further enquiries contact:
Syntaxin Ltd
Dr Charles Penn (Chief Operating Officer)
Tel +44 (0)1980 619801

Northbank Communications
Gemma Bradley, Susan Yu, Katja Stout
Tel +44 (0)20 7886 8150

About Syntaxin Ltd
Syntaxin ( was formed in November 2005 with a mission to discover, develop and commercialise novel pharmaceuticals for the treatment of disorders such as pain, COPD, asthma, Cystic Fibrosis and metabolic diseases. The company has strong technology and intellectual property foundations in the area of neurotoxins. As a spin-out from the UK Health Protection Agency (HPA), Porton Down, the company benefits from over 15 years of research in this field resulting in a proprietary molecular toolbox approach to create engineered toxins for control of cell secretion (including neurotransmission). These technologies have already produced products that have been tested in preclinical models of certain diseases states.

Resulting from its HPA origins, Syntaxin has an established executive management and scientific team which will be expanded this year to support new product development. The company earns substantial revenues from its first strategic alliance with Allergan Inc, a global specialty pharmaceutical and medical device company that develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, aesthetics, obesity intervention and other specialty markets that deliver value to its customers, satisfy unmet medical needs, and improve patients’ lives.

Syntaxin closed a £6million Series A financing in 2005 led by Abingworth Management Ltd, a leading healthcare venture firm with a proven track record in building valuable biotechnology businesses from start-up through publi

Publisher Contact Information:

Syntaxin Ltd
+44 (0)1980 619801

Company profile of Syntaxin Ltd (acquired by Ipsen)
Past press releases of Syntaxin Ltd (acquired by Ipsen).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.